NUDT15 and neoplasm: A safe 6MP dosage (i.e., 5 mg/kg/day) was continuously administered once the tumor volume reached approximately 200 mm3, the growth rate of NUDT15‐KD PC3 cells was significantly attenuated compared with scramble control (Figure 6H,I), without inducing body weight loss and leucopenia in mice (Figure 6J,K), which is the most common adverse drug reaction of 6MP.